GlassScriptPhysician profile
Anna A Niewiarowska
NPI 1003927559
$4,403.07
in general payments reported to CMS, 2019-2025
55 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.40 · 2020: $232 · 2021: $492 · 2022: $372 · 2023: $756 · 2024: $1,492 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.48 |
| Education | $293.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $521.70 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $501.93 | 2019-2025 | |
| Pfizer INC. | $272.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $229.69 | 2021-2025 | Opdivo, Krazati |
| Incyte Corporation | $215.49 | 2021-2025 | Jakafi, Niktimvo |
| Astrazeneca Pharmaceuticals LP | $197.82 | 2020-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $193.76 | 2020-2025 | Erleada, Darzalex, Carvykti |
| Gilead Sciences, INC. | $171.22 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $146.71 | 2022-2024 | Keytruda, Lynparza |
| Abbvie INC. | $133.19 | 2021-2025 | |
| Celgene Corporation | $98.06 | 2021-2023 | Opdualag, Zeposia |
| Genentech USA, INC. | $89.68 | 2020-2025 | Venclexta, Columvi, Lunsumio |
| Glaxosmithkline, LLC. | $85.60 | 2024-2025 | Ojjaara |
| Novocure INC. | $80.18 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Amgen INC. | $78.93 | 2020-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Niewiarowska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.